Details of the Drug

General Information of Drug (ID: DMR0N74)

Drug Name
LAM-002
Indication
Disease Entry ICD 11 Status REF
Chronic lymphocytic leukaemia 2A82.0 Phase 2 [1]
Non-hodgkin lymphoma 2B33.5 Phase 2 [1]
B-cell non-hodgkin lymphoma 2B33.5 Phase 1 [2]
Cross-matching ID
TTD ID
D0JW6R
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Phosphatidylinositol-3-phosphate 5-kinase (PIP5K3) TTA4M1N FYV1_HUMAN Inhibitor [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT02594384) A Phase I Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A In Patients With Non-Hodgkin's Lymphoma (LAM-002A/NHL) (LAM-002A/NHL). U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)